Candriam S.C.A. Cuts Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Candriam S.C.A. lessened its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 22.9% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 109,327 shares of the specialty pharmaceutical company’s stock after selling 32,562 shares during the quarter. Candriam S.C.A. owned about 0.20% of Supernus Pharmaceuticals worth $3,953,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of SUPN. QRG Capital Management Inc. grew its holdings in Supernus Pharmaceuticals by 6.2% in the third quarter. QRG Capital Management Inc. now owns 16,801 shares of the specialty pharmaceutical company’s stock worth $524,000 after purchasing an additional 986 shares during the period. Principal Financial Group Inc. lifted its stake in shares of Supernus Pharmaceuticals by 5.4% in the third quarter. Principal Financial Group Inc. now owns 285,411 shares of the specialty pharmaceutical company’s stock worth $8,899,000 after buying an additional 14,566 shares in the last quarter. Assetmark Inc. lifted its stake in shares of Supernus Pharmaceuticals by 2.8% in the third quarter. Assetmark Inc. now owns 33,442 shares of the specialty pharmaceutical company’s stock worth $1,043,000 after buying an additional 908 shares in the last quarter. Meritage Portfolio Management lifted its stake in shares of Supernus Pharmaceuticals by 10.8% in the third quarter. Meritage Portfolio Management now owns 44,295 shares of the specialty pharmaceutical company’s stock worth $1,381,000 after buying an additional 4,328 shares in the last quarter. Finally, State of New Jersey Common Pension Fund D bought a new position in shares of Supernus Pharmaceuticals in the third quarter worth approximately $1,774,000.

Supernus Pharmaceuticals Stock Up 0.8 %

Shares of Supernus Pharmaceuticals stock opened at $32.07 on Friday. The company has a market cap of $1.79 billion, a price-to-earnings ratio of 29.97 and a beta of 0.83. The company’s 50 day moving average is $36.70 and its 200 day moving average is $35.27. Supernus Pharmaceuticals, Inc. has a twelve month low of $25.53 and a twelve month high of $40.28.

Insider Activity at Supernus Pharmaceuticals

In related news, SVP Jonathan Rubin sold 927 shares of the stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $39.15, for a total transaction of $36,292.05. Following the transaction, the senior vice president now owns 7,853 shares in the company, valued at $307,444.95. This represents a 10.56 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Padmanabh P. Bhatt sold 9,477 shares of the stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total transaction of $376,236.90. Following the transaction, the vice president now owns 10,149 shares in the company, valued at approximately $402,915.30. This trade represents a 48.29 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 11,104 shares of company stock worth $440,263 over the last quarter. Company insiders own 9.30% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on SUPN. StockNews.com downgraded shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Cantor Fitzgerald reiterated a “neutral” rating and issued a $36.00 target price on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.